Blood tests for leftover cancer DNA to detect womb and cervical cancer returning
Studies blood tests that look for returning cancer in people with womb or cervical cancer.
Plain-language title generated from the registry record
Registry title: Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer
Key facts
- Where
- Seoul, South KoreaSee the site
Where in South Korea
- Asan Medical CenterSeoul, South KoreaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Asan Medical Center
- Trial code
- NCT07382505
- Record updated
- 2 February 2026
- Original description
This study aims to evaluate the clinical performance of blood-based Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) in patients with endometrial and cervical cancer. The researchers will investigate whether MRD detection can identify cancer recurrence earlier than current standard imaging or clinical methods (providing a "lead time"). Participants will undergo blood collection at specific time points, including at diagnosis, after surgery, and during regular follow-up visits. The study will also assess the correlation between MRD status and survival outcomes, such as Relapse-Free Survival (RFS) and Overall Survival (OS). The goal is to establish a foundation for personalized treatment strategies based on molecular monitoring.Read full original descriptionShow less
Prospective Cohort to Evaluate the Prognostic and Early-Recurrence Detection Performance of Blood-based Minimal Residual Disease (MRD) Testing in Endometrial and Cervical Cancer
This study aims to evaluate the clinical performance of blood-based Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) in patients with endometrial and cervical cancer. The researchers will investigate whether MRD detection can identify cancer recurrence earlier than current standard imaging or clinical methods (providing a "lead time"). Participants will undergo blood collection at specific time points, including at diagnosis, after surgery, and during regular follow-up visits. The study will also assess the correlation between MRD status and survival outcomes, such as Relapse-Free Survival (RFS) and Overall Survival (OS). The goal is to establish a foundation for personalized treatment strategies based on molecular monitoring.
Inclusion: Histologically confirmed endometrial cancer or cervical cancer; Scheduled for or completed standard treatment (Surgery, Adjuvant therapy, or CCRT); Provision of written informed consent for study participation and biospecimen collection.
Exclusion: Synchronous other malignancies (cancer requiring treatment within the last 5 years); Persistent infection or bleeding tendency that makes repeated blood collection unsafe; Any condition that the principal investigator deems inappropriate for the study; Inability to follow-up or communicate (e.g., due to geographic or cognitive reasons).